{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:35:04Z","timestamp":1780335304609,"version":"3.54.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-59929-2","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T10:04:37Z","timestamp":1747994677000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["PRL3-zumab as an anti-angiogenic therapy in neovascular eye diseases"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0321-1992","authenticated-orcid":false,"given":"Koon Hwee","family":"Ang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0462-9020","authenticated-orcid":false,"given":"Min","family":"Thura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Queenie Shu Woon","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0897-8366","authenticated-orcid":false,"given":"Kam Yew","family":"Kuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6404-1432","authenticated-orcid":false,"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1656-4770","authenticated-orcid":false,"given":"Pei Ling","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2662-2959","authenticated-orcid":false,"given":"Beiying","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6666-0763","authenticated-orcid":false,"given":"Jimmy Ming","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1036-2764","authenticated-orcid":false,"given":"Xiaomeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1480-6713","authenticated-orcid":false,"given":"Xinyi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8940-0275","authenticated-orcid":false,"given":"Qi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"59929_CR1","unstructured":"World report on vision. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"59929_CR2","first-page":"574","volume":"145","author":"JW Miller","year":"1994","unstructured":"Miller, J. W. et al. Vascular endothelial growth factor\/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am. J. Pathol. 145, 574\u2013584 (1994).","journal-title":"Am. J. Pathol."},{"key":"59929_CR3","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S0002-9394(14)75794-0","volume":"118","author":"AP Adamis","year":"1994","unstructured":"Adamis, A. P. et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. 118, 445\u2013450 (1994).","journal-title":"Am. J. Ophthalmol."},{"key":"59929_CR4","first-page":"875","volume":"104","author":"M Yuzawa","year":"2000","unstructured":"Yuzawa, M. Treatment of exudative age-related macular degeneration. Nippon Ganka Gakkai Zasshi 104, 875\u2013898 (2000).","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"59929_CR5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/path.4266","volume":"232","author":"M van Lookeren Campagne","year":"2014","unstructured":"van Lookeren Campagne, M., LeCouter, J., Yaspan, B. L. & Ye, W. Mechanisms of age-related macular degeneration and therapeutic opportunities. J. Pathol. 232, 151\u2013164 (2014).","journal-title":"J. Pathol."},{"key":"59929_CR6","first-page":"2156273","volume":"2016","author":"P Romero-Aroca","year":"2016","unstructured":"Romero-Aroca, P. et al. Diabetic macular edema pathophysiology: Vasogenic versus Inflammatory. J. Diab. Res 2016, 2156273 (2016).","journal-title":"J. Diab. Res"},{"key":"59929_CR7","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.tjo.2013.09.002","volume":"3","author":"X Wang","year":"2013","unstructured":"Wang, X. & Ohji, M. Vascular endothelial growth factor and its inhibitor in age-related macular degeneration. Taiwan J. Ophthalmol. 3, 128\u2013133 (2013).","journal-title":"Taiwan J. Ophthalmol."},{"key":"59929_CR8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2147\/OPTH.S128509","volume":"11","author":"KJ Blinder","year":"2017","unstructured":"Blinder, K. J. et al. Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1). Clin. Ophthalmol. (Auckl., N. Z.) 11, 393\u2013401 (2017).","journal-title":"Clin. Ophthalmol. (Auckl., N. Z.)"},{"key":"59929_CR9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/bcp.12371","volume":"78","author":"TQ Kwong","year":"2014","unstructured":"Kwong, T. Q. & Mohamed, M. Anti-vascular endothelial growth factor therapies in ophthalmology: current use, controversies and the future. Br. J. Clin. Pharm. 78, 699\u2013706 (2014).","journal-title":"Br. J. Clin. Pharm."},{"key":"59929_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.5114\/ceji.2016.63132","volume":"41","author":"D Po\u017carowska","year":"2016","unstructured":"Po\u017carowska, D. & Po\u017carowski, P. The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology. VEGF anti-VEGF Ther. Cent. Eur. J. ofnbsp;Immunol. 41, 311\u2013316 (2016).","journal-title":"VEGF anti-VEGF Ther. Cent. Eur. J. ofnbsp;Immunol."},{"key":"59929_CR11","doi-asserted-by":"crossref","unstructured":"Liberski, S., Wichrowska, M. & Koci\u0119cki, J. Aflibercept versus faricimab in the treatment of neovascular agerelated macular degeneration and diabetic macular edema: A review. Int. J. Mol. Sci. 23, 9424 (2022).","DOI":"10.3390\/ijms23169424"},{"key":"59929_CR12","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/eye.2014.13","volume":"28","author":"P Osaadon","year":"2014","unstructured":"Osaadon, P., Fagan, X. J., Lifshitz, T. & Levy, J. A review of anti-VEGF agents for proliferative diabetic retinopathy. Eye 28, 510\u2013520 (2014).","journal-title":"Eye"},{"key":"59929_CR13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/17425247.2016.1213240","volume":"14","author":"VM Villegas","year":"2017","unstructured":"Villegas, V. M., Aranguren, L. A., Kovach, J. L., Schwartz, S. G. & Flynn, H. W. Current advances in the treatment of neovascular age-related macular degeneration. Expert Opin. Drug Deliv. 14, 273\u2013282 (2017).","journal-title":"Expert Opin. Drug Deliv."},{"key":"59929_CR14","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2147\/DDDT.S115121","volume":"10","author":"S Yang","year":"2016","unstructured":"Yang, S., Zhao, J. & Sun, X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des., Dev. Ther. 10, 1857\u20131867 (2016).","journal-title":"Drug Des., Dev. Ther."},{"key":"59929_CR15","doi-asserted-by":"publisher","first-page":"981","DOI":"10.2337\/db19-1121","volume":"69","author":"M Arima","year":"2020","unstructured":"Arima, M. et al. Claudin-5 redistribution induced by inflammation leads to anti-VEGF\u2013resistant diabetic macular edema. Diabetes 69, 981 (2020).","journal-title":"Diabetes"},{"key":"59929_CR16","doi-asserted-by":"crossref","unstructured":"Nesmith, B. L. W., Ihnen, M. & Schaal, S. Poor responders to bevacizumab pharmacotherapy in age-related macular degeneration and in diabetic macular edema demonstrate increased risk for obstructive sleep apnea. RETINA 34, 2423\u20132430 (2014).","DOI":"10.1097\/IAE.0000000000000247"},{"key":"59929_CR17","doi-asserted-by":"publisher","first-page":"100906","DOI":"10.1016\/j.preteyeres.2020.100906","volume":"82","author":"PS Mettu","year":"2021","unstructured":"Mettu, P. S., Allingham, M. J. & Cousins, S. W. Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. Prog. Retinal Eye Res. 82, 100906 (2021).","journal-title":"Prog. Retinal Eye Res."},{"key":"59929_CR18","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/bjophthalmol-2011-301005","volume":"96","author":"JVG Rob","year":"2012","unstructured":"Rob, J. V. G. et al. A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. Br. J. Ophthalmol. 96, 587 (2012).","journal-title":"Br. J. Ophthalmol."},{"key":"59929_CR19","doi-asserted-by":"publisher","first-page":"e2675","DOI":"10.1371\/journal.pone.0002675","volume":"3","author":"EJ Kuiper","year":"2008","unstructured":"Kuiper, E. J. et al. The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLOS ONE 3, e2675 (2008).","journal-title":"PLOS ONE"},{"key":"59929_CR20","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1042\/CS20200308","volume":"134","author":"KB Neves","year":"2020","unstructured":"Neves, K. B., Montezano, A. C., Lang, N. N. & Touyz, R. M. Vascular toxicity associated with anti-angiogenic drugs. Clin. Sci. 134, 2503\u20132520 (2020).","journal-title":"Clin. Sci."},{"key":"59929_CR21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4161\/org.6.2.11687","volume":"6","author":"JM Rosenstein","year":"2010","unstructured":"Rosenstein, J. M., Krum, J. M. & Ruhrberg, C. VEGF in the nervous system. Organogenesis 6, 107\u2013114 (2010).","journal-title":"Organogenesis"},{"key":"59929_CR22","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1097\/IAE.0000000000002029","volume":"39","author":"C Vazquez-Alfageme","year":"2019","unstructured":"Vazquez-Alfageme, C., Nicholson, L., Hamilton, R. D. & Patel, P. J. Incidence and long-term visual acuity outcomes of retinal pigment epthelium tears after intravitreal anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration. Retina 39, 664\u2013669 (2019).","journal-title":"Retina"},{"key":"59929_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/srep16754","volume":"5","author":"J Lechner","year":"2015","unstructured":"Lechner, J. et al. Alterations in circulating immune cells in neovascular age-related macular degeneration. Sci. Rep. 5, 16754 (2015).","journal-title":"Sci. Rep."},{"key":"59929_CR24","doi-asserted-by":"crossref","unstructured":"Lin, J. B. et al. Targeting cell-type-specific, choroid-peripheral immune signaling to treat age-related macular degeneration. Cell Rep. Med. 5, 101353 (2024).","DOI":"10.1016\/j.xcrm.2023.101353"},{"key":"59929_CR25","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1167\/iovs.03-0038","volume":"44","author":"DG Espinosa-Heidmann","year":"2003","unstructured":"Espinosa-Heidmann, D. G. et al. Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest Ophthalmol. Vis. Sci. 44, 3586\u20133592 (2003).","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"59929_CR26","doi-asserted-by":"crossref","unstructured":"Hellenthal, K. E. M., Brabenec, L. & Wagner, N. M. Regulation and dysregulation of endothelial permeability during systemic inflammation. Cells 11, 1935 (2022).","DOI":"10.3390\/cells11121935"},{"key":"59929_CR27","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1002\/jcb.22913","volume":"111","author":"AQO Al-Aidaroos","year":"2010","unstructured":"Al-Aidaroos, A. Q. O. & Zeng, Q. PRL-3 phosphatase and cancer metastasis. J. Cell. Biochem. 111, 1087\u20131098 (2010).","journal-title":"J. Cell. Biochem."},{"key":"59929_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10127-x","volume":"10","author":"M Thura","year":"2019","unstructured":"Thura, M. et al. PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein. Nat. Commun. 10, 2484 (2019).","journal-title":"Nat. Commun."},{"key":"59929_CR29","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.7150\/thno.79265","volume":"13","author":"PL Chia","year":"2023","unstructured":"Chia, P. L., Ang, K. H., Thura, M. & Zeng, Q. PRL3 as a therapeutic target for novel cancer immunotherapy in multiple cancer types. Theranostics 13, 1876\u20131891 (2023).","journal-title":"Theranostics"},{"key":"59929_CR30","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1158\/1078-0432.CCR-04-1984","volume":"11","author":"J Li","year":"2005","unstructured":"Li, J. et al. Generation of PRL-3- and PRL-1-specific monoclonal antibodies as potential diagnostic markers for cancer metastases. Clin. Cancer Res. 11, 2195 (2005).","journal-title":"Clin. Cancer Res."},{"key":"59929_CR31","doi-asserted-by":"publisher","first-page":"750","DOI":"10.4161\/cbt.7.5.5764","volume":"7","author":"K Guo","year":"2008","unstructured":"Guo, K., Tang, J. P., Tan, C. P., Wang, H. & Zeng, Q. Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice. Cancer Biol. Ther. 7, 750\u2013757 (2008).","journal-title":"Cancer Biol. Ther."},{"key":"59929_CR32","doi-asserted-by":"publisher","first-page":"99ra85","DOI":"10.1126\/scitranslmed.3002296","volume":"3","author":"K Guo","year":"2011","unstructured":"Guo, K. et al. Targeting intracellular oncoproteins with antibody therapy or vaccination. Sci. Transl. Med. 3, 99ra85 (2011).","journal-title":"Sci. Transl. Med."},{"key":"59929_CR33","doi-asserted-by":"crossref","unstructured":"Thura, M. et al. PRL3-zumab, a first-in-class humanized antibody for cancer therapy. JCI Insight 1, e87607 (2016).","DOI":"10.1172\/jci.insight.87607"},{"key":"59929_CR34","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/s42003-021-02449-8","volume":"4","author":"M Thura","year":"2021","unstructured":"Thura, M. et al. PRL3 induces polypoid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse. Commun. Biol. 4, 923 (2021).","journal-title":"Commun. Biol."},{"key":"59929_CR35","doi-asserted-by":"crossref","unstructured":"Chee, C. E. et al. A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory solid tumors and hematological malignancies. Target. oncol. 18, 391\u2013402 (2023).","DOI":"10.1007\/s11523-023-00962-w"},{"key":"59929_CR36","unstructured":"NCT04118114. Phase II Study of PRL3-ZUMAB in advanced solid tumors. Vol. 2024 (ClinicalTrials.gov, ClinicalTrials.gov, 2024)."},{"key":"59929_CR37","unstructured":"NCT04452955. A study to assess safety and efficacy of PRL3-zumab in patients with solid tumors. Vol. 2024 (ClinicalTrials.gov, 2024)."},{"key":"59929_CR38","unstructured":"CTR20211180. \u4e00\u9879\u9488\u5bf9\u5b9e\u4f53\u7624\u3001\u8bc4\u4f30PRL3-Zumab\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u7684\u5f00\u653e\u6807\u7b7e\u3001\u591a\u4e2d\u5fc32\u671f\u7814\u7a76. Vol. 2024 (Chinadrugtrials, 2024)."},{"key":"59929_CR39","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4161\/cbt.3.10.1111","volume":"3","author":"K Guo","year":"2004","unstructured":"Guo, K. et al. Catalytic domain of PRL-3 plays an essential role in tumor metastasis: formation of PRL-3 tumors inside the blood vessels. Cancer Biol. Ther. 3, 945\u2013951 (2004).","journal-title":"Cancer Biol. Ther."},{"key":"59929_CR40","doi-asserted-by":"publisher","first-page":"7857","DOI":"10.1158\/0008-5472.CAN-04-1976","volume":"64","author":"BS Parker","year":"2004","unstructured":"Parker, B. S. et al. Alterations in vascular gene expression in invasive breast carcinoma. Cancer Res. 64, 7857\u20137866 (2004).","journal-title":"Cancer Res."},{"key":"59929_CR41","doi-asserted-by":"publisher","first-page":"9625","DOI":"10.1158\/0008-5472.CAN-06-0726","volume":"66","author":"K Guo","year":"2006","unstructured":"Guo, K. et al. PRL-3 initiates tumor angiogenesis by recruiting endothelial cells in vitro and in vivo. Cancer Res 66, 9625\u20139635 (2006).","journal-title":"Cancer Res"},{"key":"59929_CR42","doi-asserted-by":"publisher","first-page":"e27165","DOI":"10.1371\/journal.pone.0027165","volume":"6","author":"J Xu","year":"2011","unstructured":"Xu, J. et al. VEGF promotes the transcription of the human PRL-3 gene in HUVEC through transcription factor MEF2C. PloS one 6, e27165\u2013e27165 (2011).","journal-title":"PloS one"},{"key":"59929_CR43","doi-asserted-by":"publisher","first-page":"5904","DOI":"10.1074\/jbc.M113.480038","volume":"289","author":"MW Zimmerman","year":"2014","unstructured":"Zimmerman, M. W. et al. Protein-tyrosine phosphatase 4A3 (PTP4A3) promotes vascular endothelial growth factor signaling and enables endothelial cell motility. J. Biol. Chem. 289, 5904\u20135913 (2014).","journal-title":"J. Biol. Chem."},{"key":"59929_CR44","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1006\/dbio.1995.1180","volume":"169","author":"I Flamme","year":"1995","unstructured":"Flamme, I., Breier, G. & Risau, W. Vascular endothelial growth factor (VEGF) and VEGF receptor 2 (flk-1) are expressed during vasculogenesis and vascular differentiation in the quail embryo. Dev. Biol. 169, 699\u2013712 (1995).","journal-title":"Dev. Biol."},{"key":"59929_CR45","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.pharmthera.2016.11.008","volume":"171","author":"D Ferland-McCollough","year":"2017","unstructured":"Ferland-McCollough, D., Slater, S., Richard, J., Reni, C. & Mangialardi, G. Pericytes, an overlooked player in vascular pathobiology. Pharm. Ther. 171, 30\u201342 (2017).","journal-title":"Pharm. Ther."},{"key":"59929_CR46","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1215\/S1152851705000232","volume":"7","author":"G Bergers","year":"2005","unstructured":"Bergers, G. & Song, S. The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol. 7, 452\u2013464 (2005).","journal-title":"Neuro Oncol."},{"key":"59929_CR47","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.preteyeres.2010.05.003","volume":"29","author":"HE Grossniklaus","year":"2010","unstructured":"Grossniklaus, H. E., Kang, S. J. & Berglin, L. Animal models of choroidal and retinal neovascularization. Prog. Retin Eye Res 29, 500\u2013519 (2010).","journal-title":"Prog. Retin Eye Res"},{"key":"59929_CR48","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1038\/nprot.2009.187","volume":"4","author":"KM Connor","year":"2009","unstructured":"Connor, K. M. et al. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat. Protoc. 4, 1565\u20131573 (2009).","journal-title":"Nat. Protoc."},{"key":"59929_CR49","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.cbi.2007.08.006","volume":"171","author":"G Hu","year":"2008","unstructured":"Hu, G., Place, A. T. & Minshall, R. D. Regulation of endothelial permeability by Src kinase signaling: vascular leakage versus transcellular transport of drugs and macromolecules. Chem. Biol. Interact. 171, 177\u2013189 (2008).","journal-title":"Chem. Biol. Interact."},{"key":"59929_CR50","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1167\/iovs.03-0815","volume":"45","author":"E Aguilar","year":"2004","unstructured":"Aguilar, E. et al. Src kinase inhibition reduces laser or VEGF induced retinal vascular permeability. Investigative Ophthalmol. Vis. Sci. 45, 499\u2013499 (2004).","journal-title":"Investigative Ophthalmol. Vis. Sci."},{"key":"59929_CR51","first-page":"638","volume":"72","author":"J Pe\u2019er","year":"1995","unstructured":"Pe\u2019er, J. et al. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 72, 638\u2013645 (1995).","journal-title":"Lab Invest"},{"key":"59929_CR52","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.2337\/db13-0014","volume":"62","author":"M Rodrigues","year":"2013","unstructured":"Rodrigues, M. et al. VEGF secreted by hypoxic m\u00fcller cells induces MMP-2 expression and activity in endothelial cells to promote retinal neovascularization in proliferative diabetic retinopathy. Diabetes 62, 3863\u20133873 (2013).","journal-title":"Diabetes"},{"key":"59929_CR53","doi-asserted-by":"publisher","first-page":"e27165","DOI":"10.1371\/journal.pone.0027165","volume":"6","author":"J Xu","year":"2011","unstructured":"Xu, J. et al. VEGF promotes the transcription of the human PRL-3 gene in HUVEC through transcription factor MEF2C. PLoS One 6, e27165 (2011).","journal-title":"PLoS One"},{"key":"59929_CR54","doi-asserted-by":"publisher","first-page":"e8283","DOI":"10.1371\/journal.pone.0008283","volume":"4","author":"R Srinivasan","year":"2009","unstructured":"Srinivasan, R. et al. Erk1 and Erk2 regulate endothelial cell proliferation and migration during mouse embryonic angiogenesis. PLoS One 4, e8283 (2009).","journal-title":"PLoS One"},{"key":"59929_CR55","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.3892\/mmr.2014.2961","volume":"11","author":"WJ Yang","year":"2015","unstructured":"Yang, W. J. et al. Paxillin regulates vascular endothelial growth factor A-induced in vitro angiogenesis of human umbilical vein endothelial cells. Mol. Med Rep. 11, 1784\u20131792 (2015).","journal-title":"Mol. Med Rep."},{"key":"59929_CR56","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1083\/jcb.201404140","volume":"208","author":"O Tornavaca","year":"2015","unstructured":"Tornavaca, O. et al. ZO-1 controls endothelial adherens junctions, cell-cell tension, angiogenesis, and barrier formation. J. Cell Biol. 208, 821\u2013838 (2015).","journal-title":"J. Cell Biol."},{"key":"59929_CR57","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1161\/ATVBAHA.107.158014","volume":"28","author":"D Vestweber","year":"2008","unstructured":"Vestweber, D. VE-Cadherin. Arteriosclerosis, Thrombosis, Vasc. Biol. 28, 223\u2013232 (2008).","journal-title":"Arteriosclerosis, Thrombosis, Vasc. Biol."},{"key":"59929_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-021-00325-5","volume":"7","author":"S Arepalli","year":"2021","unstructured":"Arepalli, S. & Kaiser, P. K. Pipeline therapies for neovascular age related macular degeneration. Int. J. Retin. Vitreous 7, 55 (2021).","journal-title":"Int. J. Retin. Vitreous"},{"key":"59929_CR59","doi-asserted-by":"publisher","first-page":"e28947","DOI":"10.1371\/journal.pone.0028947","volume":"6","author":"MT Dellinger","year":"2011","unstructured":"Dellinger, M. T. & Brekken, R. A. Phosphorylation of Akt and ERK1\/2 is required for VEGF-A\/VEGFR2-induced proliferation and migration of lymphatic endothelium. PLoS One 6, e28947 (2011).","journal-title":"PLoS One"},{"key":"59929_CR60","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1084\/jem.20111343","volume":"209","author":"Z Sun","year":"2012","unstructured":"Sun, Z. et al. VEGFR2 induces c-Src signaling and vascular permeability in vivo via the adaptor protein TSAd. J. Exp. Med 209, 1363\u20131377 (2012).","journal-title":"J. Exp. Med"},{"key":"59929_CR61","doi-asserted-by":"publisher","first-page":"H434","DOI":"10.1152\/ajpheart.2001.280.1.H434","volume":"280","author":"W Wang","year":"2001","unstructured":"Wang, W., Dentler, W. L. & Borchardt, R. T. VEGF increases BMEC monolayer permeability by affecting occludin expression and tight junction assembly. Am. J. Physiol. -Heart Circulatory Physiol. 280, H434\u2013H440 (2001).","journal-title":"Am. J. Physiol. -Heart Circulatory Physiol."},{"key":"59929_CR62","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1006\/bbrc.2000.4148","volume":"280","author":"J Funyu","year":"2001","unstructured":"Funyu, J., Mochida, S., Inao, M., Matsui, A. & Fujiwara, K. VEGF can act as vascular permeability factor in the hepatic sinusoids through upregulation of porosity of endothelial cells. Biochem Biophys. Res Commun. 280, 481\u2013485 (2001).","journal-title":"Biochem Biophys. Res Commun."},{"key":"59929_CR63","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/j.1469-7793.1997.747bd.x","volume":"504","author":"D Feng","year":"1997","unstructured":"Feng, D. et al. Reinterpretation of endothelial cell gaps induced by vasoactive mediators in guinea-pig, mouse and rat: many are transcellular pores. J. Physiol. 504, 747\u2013761 (1997).","journal-title":"J. Physiol."},{"key":"59929_CR64","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/713773925","volume":"6","author":"D Feng","year":"1999","unstructured":"Feng, D. et al. Pathways of macromolecular extravasation across microvascular endothelium in response to VPF\/VEGF and other vasoactive mediators. Microcirculation 6, 23\u201344 (1999).","journal-title":"Microcirculation"},{"key":"59929_CR65","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1345\/aph.10365","volume":"35","author":"KJ Messmer","year":"2001","unstructured":"Messmer, K. J. & Abel, S. R. Verteporfin for age-related macular degeneration. Ann. Pharmacother. 35, 1593\u20131598 (2001).","journal-title":"Ann. Pharmacother."},{"key":"59929_CR66","first-page":"624","volume":"41","author":"NM Bressler","year":"2000","unstructured":"Bressler, N. M. & Bressler, S. B. Photodynamic therapy with verteporfin (Visudyne): Impact on ophthalmology and visual sciences. Investigative Ophthalmol. Vis. Sci. 41, 624\u2013628 (2000).","journal-title":"Investigative Ophthalmol. Vis. Sci."},{"key":"59929_CR67","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","volume":"138","author":"TH Lim","year":"2020","unstructured":"Lim, T. H. et al. Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: The EVEREST II randomized clinical trial. JAMA Ophthalmol. 138, 935\u2013942 (2020).","journal-title":"JAMA Ophthalmol."},{"key":"59929_CR68","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","volume":"112","author":"S Michels","year":"2005","unstructured":"Michels, S., Rosenfeld, P. J., Puliafito, C. A., Marcus, E. N. & Venkatraman, A. S. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112, 1035\u20131047 (2005).","journal-title":"Ophthalmology"},{"key":"59929_CR69","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1016\/j.ophtha.2006.05.070","volume":"113","author":"AA Moshfeghi","year":"2006","unstructured":"Moshfeghi, A. A. et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four\u2013week results of an uncontrolled open-label clinical study. Ophthalmology 113, 2002\u20132011.e2002 (2006).","journal-title":"Ophthalmology"},{"key":"59929_CR70","doi-asserted-by":"publisher","first-page":"1522.e1521","DOI":"10.1016\/j.ophtha.2006.05.055","volume":"113","author":"QD Nguyen","year":"2006","unstructured":"Nguyen, Q. D. et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113, 1522.e1521\u20131522.e1514 (2006).","journal-title":"Ophthalmology"},{"key":"59929_CR71","unstructured":"Ang, K. https:\/\/BioRender.com\/avx4snb (2025)."},{"key":"59929_CR72","unstructured":"Ang, K. https:\/\/BioRender.com\/xeucwcn (2025)."},{"key":"59929_CR73","unstructured":"Ang, K. https:\/\/BioRender.com\/t9u2tyn (2025)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59929-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59929-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59929-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T22:02:56Z","timestamp":1748037776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59929-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["59929"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-59929-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]},"assertion":[{"value":"28 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Q.Z. is the Founder, K.H.A. is the Chief Operating Officer (recent J.A.), M.T. is the Chief Medical Officer (recent J.A.), and K.K.Y is the Clinical Research Coordinator (recent J.A.) of Intra-ImmuSG Pte Ltd., an Agency for Science, Technology and Research (A*STAR) spin-off company granted licensing rights for the PRL3-zumab IP portfolio. The other authors declare no competing interests. J.A.: Joint Appointment.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4791"}}